- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Telisotuzumab Vedotin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 40
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Los Angeles, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma
- Interventions
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- AMT-116, Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)
- Drug
- Lead sponsor
- Multitude Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Port Saint Lucie, Florida • Kingwood, Texas
- Conditions
- Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC
- Interventions
- HWK-007
- Drug
- Lead sponsor
- Whitehawk Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Telisotuzumab Vedotin, Docetaxel
- Biological · Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 768 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 46 more